Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Catabasis Uses New Financing To Take Two Programs Forward Simultaneously

This article was originally published in The Pink Sheet Daily

Executive Summary

The biotech now has the funding to move a second program into the clinic; a program it hopes to carry to approval on its own.

You may also be interested in...



Amarin Seeks AMR101 Approval; Hopes To Begin Commercialization Of First Product

The New Jersey biotech submitted the NDA for its omega-3 fatty acid drug with FDA.

As It Soaks Up Good Trial Results, Amarin Ponders Partners - Or None

A second set of clinical trial results expands the potential market for AMR101 tenfold, triggering increased investor and partnership interest.

Will The Rising Tide Of Rx Omega-3s Float The Fish Oil Supplement Market?

Nutritional industry stakeholders say the jury is still out on how omega-3 pharmaceuticals will affect the supplement space long-term, but supplement marketers should do everything they can to step up their game.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel